Corvus Pharmaceuticals (NASDAQ:CRVS) Director David Scott Moore Buys 21,700 Shares

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director David Scott Moore purchased 21,700 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the purchase, the director directly owned 21,700 shares of the company’s stock, valued at approximately $250,201. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $11.90 on Tuesday. The business’s 50 day moving average price is $13.95 and its 200-day moving average price is $13.71. The firm has a market capitalization of $1.00 billion, a PE ratio of -22.88 and a beta of 0.84. Corvus Pharmaceuticals, Inc. has a 1 year low of $3.55 and a 1 year high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, analysts expect that Corvus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP acquired a new position in Corvus Pharmaceuticals during the third quarter worth $27,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Corvus Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after buying an additional 748 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Corvus Pharmaceuticals during the third quarter worth $49,000. Sender Co & Partners Inc. acquired a new position in Corvus Pharmaceuticals during the second quarter worth $52,000. Finally, Bayesian Capital Management LP acquired a new position in Corvus Pharmaceuticals during the second quarter worth $70,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Friday, March 13th. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Oppenheimer reissued an “outperform” rating and set a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a research note on Friday, March 13th. The Goldman Sachs Group initiated coverage on Corvus Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Wall Street Zen lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.